Universal Vision Biotechnology Co., Ltd. (TPEX:3218)
192.00
-1.50 (-0.78%)
Aug 15, 2025, 2:31 PM CST
TPEX:3218 Revenue
Universal Vision Biotechnology had revenue of 1.02B TWD in the quarter ending June 30, 2025, a decrease of -1.59%. This brings the company's revenue in the last twelve months to 4.26B, up 2.37% year-over-year. In the year 2024, Universal Vision Biotechnology had annual revenue of 4.23B with 3.58% growth.
Revenue (ttm)
4.26B
Revenue Growth
+2.37%
P/S Ratio
3.82
Revenue / Employee
10.63M
Employees
401
Market Cap
16.27B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.23B | 146.05M | 3.58% |
Dec 31, 2023 | 4.08B | 588.20M | 16.83% |
Dec 31, 2022 | 3.49B | 862.26M | 32.76% |
Dec 31, 2021 | 2.63B | 578.66M | 28.18% |
Dec 31, 2020 | 2.05B | 634.16M | 44.69% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Caliway Biopharmaceuticals | 44.83M |
PharmaEssentia | 12.63B |
Bora Pharmaceuticals Co., LTD. | 21.32B |
Lotus Pharmaceutical | 19.12B |
Oneness Biotech | 112.57M |
Lumosa Therapeutics | 37.25M |
Polaris Group | 87.67M |
Center Laboratories | 1.63B |